Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

NCT00625651 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
Colon Cancer
Colorectal Cancer
Rectal Cancer

Interventions

DRUG: Placebo
DRUG: AMG 655
DRUG: Modified FOLFOX6
DRUG: Bevacizumab

Sponsor

Amgen